RTP Mobile Logo
Submitted by web@researchtop... on Tue, 05/29/2018 - 11:41
VPB118

Discussion with Sara M Tolaney, MD, MPH and Sulfi Ibrahim, MD

Track 1: Case: A 64-year-old woman presents with de novo ER-positive, HER2-negative breast cancer and bone metastases
Track 2: Selection of therapy for patients with de novo ER-positive metastatic breast cancer (mBC)
Track 3: Efficacy and tolerability of the CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib
Track 4: Activity and side effects of palbociclib/letrozole for ER-positive mBC
Track 5: Perspective on removal of the primary tumor in patients with metastatic disease
Track 6: Viewpoint on switching CDK4/6 inhibitors for patients experiencing disease progression
Track 7: Investigation of CDK4/6 inhibitors in the adjuvant setting
Track 8: Activity of CDK4/6 inhibitors in patients with brain metastases
Track 9: Case: A 65-year-old woman with ER-positive, HER2-negative mBC and a PIK3CA mutation
Track 10: Molecular profiling for patients with relapsed ER-positive mBC
Track 11: Use of abemaciclib monotherapy after disease progression on palbociclib
Track 12: Ongoing investigation of PI3K inhibitors for ER-positive mBC
Track 13: BRCA mutation testing for patients with ER-positive mBC
Track 14: Case: A 65-year-old woman receiving palbociclib/anastrozole for ER-positive, HER2-negative mBC has to discontinue palbociclib because of intolerance
Track 15: Palbociclib-associated side effects
Track 16: Therapeutic options for patients with ER-positive mBC who experience disease progression on a CDK4/6 inhibitor
Track 17: Case: A 75-year-old man with ER-positive, HER2-negative breast cancer and metastatic disease to the chest wall
Track 18: Incidence and presentation of ER-positive breast cancer in men
Track 19: Efficacy of CDK4/6 inhibitors in men with ER-positive breast cancer
Track 20: Management of ER-positive, HER2-negative breast cancer in men
Track 21: Case: A 64-year-old woman initially diagnosed with ER-positive, HER2-negative breast cancer experiences a change in HER2 status during the course of metastatic disease
Track 22: Activity of everolimus/exemestane in patients with ER-positive mBC
Track 23: Selection of endocrine therapy for patients with HER2-positive breast cancer
Track 24: Role of CDK4/6 inhibitors in the treatment of ER-positive, HER2-positive mBC
Track 25: Case: A 54-year-old woman with ER-positive, HER2-negative mBC whose disease progresses through multiple rounds of therapy is found to harbor an ESR1 mutation and hENT1 amplification
Track 26: Treatment options for patients with ER-positive mBC and ESR1 mutations
Track 27: Role of immune checkpoint inhibitors in the treatment of ER-positive mBC

Discussion with Kathy D Miller, MD and Laila Agrawal, MD

Track 1: Case: A 70-year-old woman receives palbociclib/letrozole for ER-positive, HER2-negative mBC
Track 2: Emergence of ESR1 mutations in breast cancer progression
Track 3: Clinical significance of estrogen receptor mutations
Track 4: Mechanisms of resistance to endocrine therapy
Track 5: Biologic rationale for the use of mTOR and CDK4/6 inhibitors for ER-positive mBC
Track 6: Selection of CDK4/6 inhibitors for patients with ER-positive mBC
Track 7: Schedule of administration and CNS activity of abemaciclib
Track 8: Role of abemaciclib monotherapy in the treatment of ER-positive mBC
Track 9: Side effects associated with CDK4/6 inhibitors
Track 10: Case: A 57-year-old woman initially diagnosed with ER-positive, HER2-negative localized breast cancer develops rapidly progressive metastasis to the chest wall that is biopsy-proven to be triple-negative
Track 11: PI3K mutations and implications for therapy
Track 12: Management of ER-positive breast cancer with chest wall metastases
Track 13: Case: A 61-year-old woman who received 1 year of adjuvant tamoxifen for ER-positive, HER2-negative breast cancer develops metastatic disease 20 years later
Track 14: Effect of tamoxifen therapy duration on breast cancer recurrence
Track 15: Effect of behavioral counseling on patient attitude and quality of life
Track 16: Case: A 73-year-old woman diagnosed with Stage IIIC ER-positive breast cancer in 1995 experiences recurrence 6 years later with metastases to the spine
Track 17: Management of stomatitis/mucositis and pneumonitis associated with everolimus
Track 18: Therapeutic options for patients with ER-positive mBC after disease progression on everolimus/exemestane
Track 19: High-dose estrogen therapy for patients with ER-positive mBC
 
CLINICAL INVESTIGATORS
 
Sara M Tolaney, MD, MPH
Dana-Farber Cancer Institute
Associate Director of Clinical Research
Susan F Smith Center for Women’s Cancers
Senior Physician
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts
 
Kathy D Miller, MD
Co-Director
IU Simon Cancer Center Breast Cancer Program
Ballvé-Lantero Scholar in Oncology
Professor of Medicine
Division of Hematology/Oncology
The Indiana University Melvin
and Bren Simon Cancer Center
Indianapolis, Indiana
 
CONSULTING ONCOLOGISTS
 
Sulfi Ibrahim, MD
Hematology Oncology of Indiana
Indianapolis, Indiana
 
Laila Agrawal, MD
Norton Healthcare
Louisville, Kentucky
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida